24.08.2010 • News

Evonik to Expand Production Capacities in China

Demand for triacetonamine derivatives (TAA derivatives) has kept rising for several years. Evonik Industries is taking advantage of the economic opportunities afforded by this situation and is considerably expanding its production capacities for these special derivatives in China. The foundations for a new plant will be laid as early as this year.

Currently, Evonik produces the derivatives in a joint venture Evonik Tianda (Liaoyang) Chemical Additive at the Liaoyang site in northeastern China. The existing production capacities are to be moved within the Liaoyang region to the Aromatic Site (LAS), one of the country's largest petrochemical sites. Furthermore, production will be significantly increased. Full production is scheduled to commence in the fourth quarter of 2011.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

Special Issue

Circular Plastics Economy
Explore the Future of Plastics

Circular Plastics Economy

This special CHEManager issue explores the industry’s pivotal shift towards a more sustainable, circular plastics value chain. Readers will find expert analysis and real-world solutions for today’s most pressing recycling and regulatory challenges.

most read